The company’s key strategic business objectives include global Launch of KALYDECO in Cystic Fibrosis and expansion of its KALYDE
Last Updated by Anonymous | Update This Page Delete This Page
… "The company’s key strategic business objectives include global Launch of KALYDECO in Cystic Fibrosis and expansion of its KALYDE" has a significant impact, so an analyst should put more weight into it. This statements will have a short-term positive impact on this entity, which adds to its value.
SWOT Analysis Survey
SWOT Strength: The company’s key strategic business objectives include global Launch of KALYDECO in Cystic Fibrosis and expansion of its KALYDE
[[div class="delete-prompt" style="display : none;"]]
If you believe that this point is inaccurate, please flag this page to notify administrators and moderators.
